355 citations
,
January 2017 in “Journal of the American Academy of Dermatology” JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.
277 citations
,
December 2019 in “Frontiers in Immunology” JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.
51 citations
,
October 2019 in “Cells” Baricitinib reduces inflammation and improves cell health in premature aging cells.
13 citations
,
January 2020 in “Acta Dermato Venereologica” Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.
6 citations
,
October 2024 in “Journal of Family Medicine and Primary Care” Primary care doctors need to monitor JAK and TYK-2 inhibitors carefully for skin conditions.
6 citations
,
November 2022 in “Journal of autoimmunity” JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
2 citations
,
March 2026 in “Journal of Dermatological Treatment” JAK inhibitors for alopecia areata have different safety risks, requiring specific monitoring for each drug.
2 citations
,
June 2023 in “Indian journal of dermatology, venereology, and leprology” Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.
1 citations
,
September 2024 in “IP Indian Journal of Clinical and Experimental Dermatology” Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.
1 citations
,
October 2023 in “Dermatology and therapy” Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
May 2026 in “Journal of Skin and Sexually Transmitted Diseases” Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
January 2025 in “Balkan Medical Journal” Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.
October 2024 in “Clinical Cosmetic and Investigational Dermatology” Brevilin-A is a safe and effective treatment for mild to moderate alopecia areata in children.
June 2024 in “Poster presentations” Janus Kinase inhibitors effectively induce remission in Ulcerative Colitis with an acceptable safety profile.
January 2024 in “Journal of Clinical Images and Medical Case Reports” Baricitinib may help treat frontal fibrosing alopecia and facial papules.
53 citations
,
July 2018 in “Drug design, development and therapy” Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.
February 2026 in “Frontiers in Immunology” Ivarmacitinib significantly improved hair regrowth in severe alopecia areata after tofacitinib was less effective.
December 2025 in “Dermatology The American Medical Journal” JAK inhibitors are effective for long-term management of alopecia areata.
September 2023 in “Frontiers in medicine” The mTOR signaling pathway is crucial for hair health and targeting it may lead to new hair loss treatments.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
82 citations
,
March 2016 in “Autoimmunity reviews” Animal models have helped understand hair loss from alopecia areata and find new treatments.
77 citations
,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
63 citations
,
July 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
52 citations
,
September 2018 in “International Journal of Molecular Sciences” Ginseng and its compounds may help hair growth and prevent hair loss, but more human trials are needed to confirm this.
45 citations
,
October 2018 in “JCI Insight” Entospletinib effectively prevents eye and skin GVHD in mice.
40 citations
,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
38 citations
,
June 2015 in “Expert Opinion on Therapeutic Targets” Blocking the prolactin receptor might help treat various diseases, but more research is needed.
32 citations
,
April 2019 in “JAAD case reports” JAK inhibitors helped treat hair loss in two people with Down syndrome.